The University of Notre Dame Australia

ResearchOnline@ND
Medical Papers and Journal Articles

School of Medicine

2018

Accuracy of multiparametric magnetic resonance imaging to detect
significant prostate cancer and index lesion location
Hariette Goldman
The University of Notre Dame Australia, hariette.goldman@nd.edu.au

Neha Singh
Catherine Harding
University of Notre Dame Australia, Catherine.Harding@nd.edu.au

Joe McGirr
The University of Notre Dame Australia, joe.mcgirr@nd.edu.au

Alexa Seal
The University of Notre Dame Australia, alexa.seal@nd.edu.au

See next page for additional authors

Follow this and additional works at: https://researchonline.nd.edu.au/med_article
Part of the Medicine and Health Sciences Commons
This article was originally published as:
Goldman, H., Singh, N., Harding, C., McGirr, J., Seal, A., Duncan, I., & Sowter, S. (2018). Accuracy of multiparametric magnetic
resonance imaging to detect significant prostate cancer and index lesion location. ANZ Journal of Surgery, Early View (Online First).
Original article available here:
10.1111/ans.14754

This article is posted on ResearchOnline@ND at
https://researchonline.nd.edu.au/med_article/989. For more
information, please contact researchonline@nd.edu.au.

Authors
Hariette Goldman, Neha Singh, Catherine Harding, Joe McGirr, Alexa Seal, Ian Duncan, and Steven Sowter

This article is available at ResearchOnline@ND: https://researchonline.nd.edu.au/med_article/989

This is the peer reviewed version of the following article:
Goldman, H., Singh, N., Harding, C., McGirr, J., Seal, A., Duncan, I., and Sowter, S. (2018).
Accuracy of multiparametric magnetic resonance imaging to detect significant prostate
cancer and index lesion location. ANZ Journal of Surgery, Online First. doi: 10.1111/ans.14754
This article has been published in final form at: https://doi.org/10.1111/ans.14754

This article may be used for non-commercial purposes in accordance with Wiley Terms and
Conditions for self-archiving.

Accuracy of multiparametric magnetic resonance imaging to detect significant
prostate cancer and index lesion location
Hariette Goldman1, Neha Singh1,2, Catherine Harding1, Joe McGirr1, Alexa Seal1, Ian Duncan2 and
Steven Sowter3¶
1School

of Medicine Sydney, The University of Notre Dame Australia, Rural Clinical School Wagga
Wagga, New South Wales, Australia

2Calvary

Healthcare Regional Imaging, Wagga Wagga, New South Wales, Australia
3Riverina

Urology, Wagga Wagga, New South Wales, Australia

Correspondence to: Dr Hariette Goldman, School of Medicine, The University of Notre Dame
Australia, 160 Oxford Street, Darlinghurst, NSW 2010, Australia. hariette.goldman@gmail.com

Abstract
Background: Multiparametric magnetic resonance imaging (mpMRI) of the prostate appears to
improve prostate cancer detection, but studies comparing mpMRI to histopathology at the time of
radical prostatectomy (RP) are lacking. This retrospective study determined the accuracy of mpMRI
predicting Gleason score and index lesion location at the time of RP, the current gold standard for
diagnosis.
Methods: Between April 2013 and April 2016, a database of all men aged more than 40 years who
underwent RP after positive transrectal ultrasound biopsy by an experienced urological surgeon was
collated at a single regional centre. This was cross-referenced with a database of all men who had
mpMRIs performed at a single centre and reported according to Prostate Imaging Reporting and Data
System (PI-RADS version 1) during this period to generate a sample size of 64 men. A Spearman’s
rho test was utilized to calculate correlation.
Results: Median age of patients was 64 years, the median prostate-specific antigen at RP was 6.22
ng/mL. mpMRI was positive (≥PI-RADS 3) in 85.9% of patients who underwent RP. More than 92% of
participants had Gleason ≥7 disease. A positive relationship between mpMRI prostate PI-RADS score
and RP cancer volume was demonstrated. An anatomical location correlation calculated in octants
was found to be 89.1% accurate.
Conclusion: mpMRI accurately detects prostate cancer location and severity when compared with
gold standard histopathology at the time of RP. It thus has an important role in planning for future
prostate biopsy and cancer treatment.
Key words: anatomical correlation, biopsy, cancer detection, magnetic resonance imaging, prostate
cancer.

Introduction
Over the last 10 years, multiparametric magnetic resonance imaging (mpMRI) of the prostate has
emerged as a tool for the assessment and diagnosis of focal prostate cancer (PCa), especially amidst
concerns about the accuracy of screening measures [1].
Interest in the accuracy of PCa assessment using mpMRI has increased in response to the low
specificity/sensitivity of digital rectal examination [2] and issues with transrectal ultrasound (TRUS)guided prostate biopsy, including inadequate sampling of the anterior part of the prostate and the
disparity between Gleason score at biopsy and pathological analysis at the time of radical
prostatectomy (RP) [2–4]. There have been multiple recent studies published about the diagnostic
accuracy of mpMRI, comparing preoperative MRI findings with biopsy results and cohorts of RP
histopathology [5–7]. The aforementioned literature demonstrated that mpMRI had high sensitivity
and high negative predictive value for detecting PCa, with limited specificity [4].
mpMRI compares favourably with established tests such as mammography for breast cancer
screening [8]. It has been demonstrated that men in regional areas receive PCa diagnoses later,
receive delayed treatment and have increased morbidity and mortality when compared with men in
metropolitan areas [9]. Therefore, it is important to explore and contextualize the role of mpMRI in a
regional setting where risk stratification for biopsy and treatment must be performed with access and
resource limitations in mind. The current gold standard treatment for clinically significant, nonmetastatic PCa is aimed at total removal of the gland via RP, with pelvic lymph node clearance
[10,11]. This retrospective study utilized RP specimens to correlate Prostate Imaging Reporting and
Data System (PI-RADS) score with definitive Gleason score and PCa volume. It also aims to
document the accuracy of mpMRI by demonstrating anatomical concordance between mpMRI and
RP pathology.

Methods
Study population characteristics
Between April 2013 and April 2016, a database of all men who underwent RP by an experienced
urological surgeon after positive biopsy was collated at a regional centre. A database of patients who
underwent mpMRI for clinical suspicion of PCa was also collated. These databases identified 64
patients aged ≥40 years who underwent mpMRI prostate within 18 months prior to RP. The surgeon
used mpMRI to guide TRUS cognitive-fusion biopsy, informing the decision to proceed to RP.
Regions of interest (ROI) appeared visible on TRUS as a hypoechoic area, which assisted targeted
biopsy.
Exclusion criteria included men who had their first mpMRI prostate post radiotherapy, men who had
mpMRI but had not yet undergone RP and men with an mpMRI prostate reported by an inexperienced
radiologist (less than 50 mpMRI previously reported).

All procedures performed in studies involving human participants were in accordance with the ethical
standards of the institutional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments. Ethics approval was granted by The University of Notre Dame
Australia’s Human Research Ethics Committee. Informed consent was gained from all patients prior
to their database inclusion.
Study protocol
mpMRIs were performed at a single centre using the Discovery MR750w 3.0T (GE Healthcare,
Chicago, IL, USA), 3-Tesla magnet and a standardized protocol as per published mpMRI prostate
studies [1,5]. In RP-naïve men, a cognitive-fusion biopsy with 16–24 cores was utilized to obtain a
Gleason score. Indications for RP adhered to a definition of clinically significant PCa. Significant PCa
was defined as either Gleason score ≥7, PCa volume >0.5 cm3 at RP specimen analysis or extraprostatic extension, in line with current literature [2,4,11].
MRI was prospectively anatomically correlated to RP in octants. The data collectors entering mpMRI
and RP anatomic locations were blinded to prevent bias. An index lesion (IL) based on size was
analysed on a per-patient basis for apparent diffusion coefficient and RP specimen. RP
histopathology was performed at two regional centres as per established World Health Organization
(WHO) reporting guidelines.
Reporting protocol
Two radiologists (ID and NS) reported mpMRIs independently as ordered by the clinician (SS). Each
radiologist had reported more than 50 prior prostate MRIs. Standard PI-RADS version 1 was used.
Radiologists were given clinical data including PSA, digital rectal examination and family history.
Standardized PI-RADS is on a five-point scale, which describes clinically significant PCa; 1, extremely
unlikely; 2, unlikely; 3, equivocal; 4, likely or 5, extremely likely [12]. Using objective criteria, ROI were
assigned a score for each parameter including T2-weighted imaging (T2WI), dynamic contrastenhanced imaging and diffusion weighted imaging. For the purpose of the study, positivity was
defined as PI-RADS ≥3, in line with other mpMRI prostate studies [3,4,13–16]. The study’s primary
end point was to demonstrate a correlation between PI-RADS and Gleason score/PCa volume.
A blinded investigator correlated location according to retrospective mpMRI radiology reports and
pathology reports. MRI ILs were retrospectively defined by the investigator as lesions with the highest
PI-RADS score. The prostate was divided into octants at histopathology to characterize IL. mpMRI ILs
were described in octants in order to determine correlation between mpMRI and RP specimen.
Secondary lesions were reported descriptively.
Statistical analysis
Statistics were performed using Microsoft Excel Professional Plus 2013 (Windows 10 Enterprise;
Microsoft, Redmond, WA, USA) and IBM SPSS version 22 (IBM, Armonk, NY, USA). Tests were twotailed and a p-value of <0.05 was considered significant. A Spearman’s rank correlation was utilized

to determine the correlation between PI-RADS and Gleason score at TRUS biopsy and RP, and PIRADS and PCa volume at RP given the distribution of the data. A Kruskal–Wallis H-test was used to
assess statistical difference between PI-RAD categories and mean PCa volume.

Results
Baseline characteristics
The median age of the study population was 64 (35–79) years, and 92% of participants had at least
Gleason 7 disease. The median PSA at the time of surgery was 6.22 ng/mL. Seventy-five percent of
patients had a volume of PCa >0.5 cm3 at RP histopathology.
Biopsy results
There was 75% correlation between cognitive-fusion biopsy Gleason score and RP specimen
Gleason score. Of the 16 patients whose Gleason scores did not correlate, 13 were upgraded from
biopsy to RP. This corresponded to a 20.3% rate of Gleason score upgrade from biopsy to RP. Table
1 shows a cross-tabulation of the distribution of biopsy Gleason results within PI-RADS score
categories.
RP specimen results
Sixty-four patients underwent RP after mpMRI and TRUS biopsy. Table 1 demonstrates the
distribution of Gleason scores at the time of RP specimen histopathology and their percentage within
each PI-RADS score category. The five patients who were found to have Gleason 6 disease were all
found to have PCa volumes ≥0.5 cm3.

Table 1: Gleason score at biopsy and at radical prostatectomy according to PI-RADS
PI-RADS [n (%)]

Gleason Score

2

3

4

5

6

3 (33.3)

1 (9.1)

4 (25.0)

8 (28.6)

7

4 (44.4)

9 (81.8)

12 (75.0)

15 (53.6)

8

2 (22.2)

1 (9.1)

0

2 (7.1)

9

0

0

0

3 (10.7)

6

2 (22.2)

1 (9.1)

0

2 (7.1)

At radical

7

5 (55.6)

10 (90.9)

16 (100)

22 (78.6)

prostatectomy

8

2 (22.2)

0

0

1 (3.6)

9

0

0

0

3 (10.7)

At biopsy

Forty-six (71.9%) patients had PCa volumes ≥0.5 cm3 at the time of RP specimen analysis. Figure 1
demonstrates the relationship between PCa and volume at RP when compared with mpMRI PIRADS.

Significant PCa (volume ≥0.5 cm3) was found in 55.6% of patients reported as PI-RADS 2, 54.5% of
patients reported as PIRADS 3, 87.5% of patients reported as PI-RADS 4 and 82.1% of patients
reported as PI-RADS 5.
There was no correlation between PI-RADS and Gleason scores; however, there was a positive
correlation between PI-RADS score and PCa volume (Spearman’s ρ = 0.356, p = 0.004). Gleason
score was also positively associated with PCa volume (Spearman’s ρ = 0.347, p = 0.005).
Cancer volume increased with increasing PI-RADS score (p = 0.018). Mean cancer volume at the
time of RP histopathology was reported as 0.79 cm3 for PI-RADS 2 PCa, 0.95 cm3 for PIRADS 3
PCa, 1.87 cm3 for PI-RADS 4 PCa and 2.47 cm3 for PIRADS 5 PCa.
There were nine patients whose PCa was reported as insignificant (PI-RADS 2), of whom seven were
found to have ≥Gleason 7 disease at RP. Fifty-five patients had significant disease on mpMRI (≥PIRADS 3), three of whom had Gleason 6 disease reported at RP.
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Figure 1: Prostate cancer volume versus Prostate Imaging Reporting and Data System (PI-RADS)
score.

Correlation location
Fifty-seven (89.1%) patients had an IL described on mpMRI that corresponded with the IL reported at
RP. Table 2 describes features of ILs on mpMRI that did not correspond with IL at RP. Seven
significant PCas found at RP were not identified on mpMRI (Table S1). The majority (5/7) of

significant PCa missed was intermediate risk with Gleason score 3 + 4 = 7 (n = 3) or Gleason 4 + 3 =
7 (n = 1). Two patients were found to have Gleason 8 disease at the time of RP. Both patients had an
mpMRI demonstrating diffuse low-grade signal abnormality, attributed to benign glandular
hyperplasia.

Table 2: MRI IL versus radical prostatectomy IL locations
Patient No.

4

10

MRI IL

Other regions
MRI

Left anterolateral

Left anterior

mid

apex

Left posterior

Right PZ

RP IL

Postero-lateral right

Other regions
RP
Left posterior
apex

Right posterior
peripheral

Diffuse bilateral
30

non-specific

-

Posterior–left and right

-Right PZ

change
33

40

Central bilateral

Left PZ

Minor left and right
change
Left base with

45

seminal vesical
invasion

56

Apex, peripheral zones
bilaterally
Multifocal cancer in all
quadrants, largest
volume in right PZ
Left and right apex, no
seminal vesical invasion

Diffuse central

Extensive bilaterally in

gland abnormality

PZ

Foci in left and
right posterior
quadrants

IL - index lesion; MRI – magnetic resonance imaging; PZ – peripheral zone

Discussion
Accurately sampling the prostate during biopsy has become increasingly important amidst concerns
that men are presenting later and with more advanced disease as a result of the recommendations
against routine PSA screening released in 2012 [1].
mpMRI prostate has been widely adopted by Australian urologists to characterize PCa prior to initial
biopsy, with approximately one in five urologists ordering pre-biopsy MRI in 2015 [17]. Its use has
been promoted by the Urological Society of Australia and New Zealand (USANZ) to aid cognitivefusion or in-gantry biopsy for active surveillance of low-risk disease and to stage newly diagnosed
PCa [18]. USANZ lodged an application to the Medicare Benefits Schedule for funding both cognitivefusion and in-gantry MRI biopsies which was only recently opposed in April 2017 [19].

In this study, the primary surgeon utilized mpMRI to guide cognitive-fusion TRUS biopsy. This is a
widely accessible technology, which allows the surgeon to prioritize the ROI pre-identified on mpMRI.
Our study demonstrated a significant positive correlation between PI-RADS score and PCa volume at
the time of RP. Tumour volume was not assessed on MRI in this patient group but the PI-RADS score
itself contains a relevant quantitative component, with increasing PI-RADS score indicating increasing
capsular contact by the PCa [8].
There are limited published studies reporting anatomical correlation between lesions with a high PIRADS and IL at RP histopathology [1,15,20]. One retrospective study comparing cognitive-fusion
biopsy of 63 patients with robotic RP whole-mount pathology found MRI was anatomically accurate in
73% of cases [21]. Patel et al. [21] mapped the prostate into 24 segments on MRI and histopathology
to correlate ILs, which likely accounts for its decreased accuracy compared with our study, despite a
similar sample size. Thompson et al. compared ROIs in the transperineal template-guided mapping
biopsy and whole-mount RP histopathology of 109 men with an 18-segment prostate map and found
97% anatomical concordance, of which 86.5% matched exactly and 13.5% matched but had separate
missed significant PCa on MRI [16]. This breakdown of results would have been a useful addition to
the data collected by our investigators, but we were unable to confidently correlate the results, given
we retrospectively defined the MRI IL. Whole-mount pathology was not available to us at our regional
pathology provider. In the current study, the prostate was divided into octants in order to describe
lesions, as this is how they were reported at the time of histopathological analysis.
PCa is the only solid organ malignancy that is diagnosed by blind biopsy, i.e. without visualization of
the tumour [22]. Without image guidance, systematic TRUS biopsy inadequately samples lesions in
the apex, anterior and midline of the prostate [23]. Attempts to increase sampling with additional cores
can increase morbidity from bleeding [24] and lower urinary tract symptoms and infection, with
readmission rates as high as 2% [3,25]. The inaccuracy of blind biopsy is evident in the frequent
disparity between biopsy Gleason score at biopsy when compared to RP, with a recent study of 5339
cases finding only 54.5% concordance [26].
Techniques proposed to increase accuracy include increasing biopsy cores (16, 24, 28 or 36), MRI
prior to standard TRUS biopsy with additional targeted cores and ultrasound/MRI (cognitive) fusion
biopsies, designed to improve the specificity of the lesions targeted [8,16]. There is no consensus on
the optimal core number for PCa detection without an increase in morbidity, which ranges between 12
and 36 for some template-mapped and perineal biopsy protocols [7,15,25,27]. The primary operator
has reduced from an 18–24 core biopsy protocol to an aforementioned 12 core with four additional
cores in mpMRI identified ROIs.
This research adds to the body of evidence that IL can be identified on prostate mpMRI prior to TRUS
biopsy and RP in the majority of men. The ability of mpMRI to accurately detect the anatomical
location of PCa ILs is important for cognitive-fusion biopsy, where the urologist uses ‘visual
registration’ to aim biopsy cores at known mpMRI targets. This technique is simple, inexpensive and
does not require additional equipment [28]. 89.1% of patients’ IL was correctly identified on mpMRI

prior to TRUS biopsy and RP, which supports the validity of targeted cognitive fusion biopsy by an
experienced operator.
Cognitive-fusion biopsy is more readily available in regional centres, given the absence of
transperineal biopsy mapping and in-gantry biopsy techniques. Utilizing this technique with 12–18
cores is less time-consuming, less costly and involves a reduced general anaesthesia time for the
patient when compared with techniques aforementioned [23,25]. Whilst access to specialist and
radiology services is improving in Australian regional centres, there is a recognized discrepancy
between Medicare-funded services, health workforce and individual health status between rural and
metropolitan areas [28].
There is minimal extra requirement of urologists, radiographers or local health services when utilizing
cognitive-fusion biopsy. Ultrasound-MRI fusion and in-gantry biopsy techniques require more ancillary
staff including appropriately trained radiographers and registered nurses. Additionally, the Medical
Services Advisory Committee costed these three procedures at $925.72, $1149.72 and $2375.11,
respectively [19]. Cognitive-fusion biopsy is a sensible option to reduce the human and financial cost
whilst maintaining accuracy.
There is ongoing debate about the reference standard to which mpMRI is compared [28]. A
systematic review found that ‘various authors advocate comparing MRI with transrectal biopsy, TPB
or prostatectomy specimens’ but concluded that even studies which compared both biopsy and RP
specimens to MRI produced similar results, a high negative predictive value of MRI specimens
[2,4,14–16,18,24,28]. Transperineal biopsy can provide a more comprehensive sample of the prostate
for comparison [24]. This was a limitation of our study; however, it is not currently available in regional
New South Wales centres.
In this study, there was no significant correlation between PIRADS and Gleason score at RP, likely
due to the skew of our small sample size towards Gleason 7 disease, reducing the spread at the
higher Gleason range. However, the characteristics of patients who underwent RP were similar to
other studies conducted in tertiary centres [4,15,17,18,20].
Four patients who had Gleason ≥7 with volumes >0.5 cm3 were reported as PI-RADS 2 on initial
mpMRI. A limitation of this retrospective study was the presence of sample bias. All patients in our
study population had significant PCa, thus a high false negative rate. This indicates that although
mpMRI enables the targeted sampling of potential PCa focus, it is not a reliable substitute for initial
biopsy.
At the time of database collation, PI-RADS version 1 was the most current reporting system [20]. PIRADS version 2 (2015) places greater emphasis on T2WI and DWI for PCa detection in the transition
peripheral zones and places less emphasis on DCE [7,17] which was weakly correlated in this study
compared with T2WI and DWI. Our findings support the changes made to the PI-RADS reporting
score.

Conclusions
mpMRI was able to detect clinically significant PCa with greater accuracy for PCa volume than
Gleason score. Location correlation between mpMRI IL and RP specimen tumour focus demonstrated
high accuracy in a small sample size. This study supports the use of cognitive-fusion biopsy,
especially in regional centres with limited access to in-bore MRI or MRI-ultrasound fusion technology.
Further prospective studies comparing mpMRI cognitive-fusion biopsy with RP specimens are needed
to support more widespread use of mpMRI-targeted biopsy in clinical practice.
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Table S1: Features of significant prostate cancer missed on mpMRI
Patient
Number
3

PI-RADS
Score
2

Gleason
Score
7

Volume
(cm3)
0.1

PSA
(ng/mL)
2.8

12

2

7

0.7

6.4

45

2

8

2.0

7.0

50

2

7

0.2

4.8

52

2

7

0.8

6.6

55

2

8

0.8

8.1

64

2

7

0.2

4.8

